Sign Up Today and Learn More About Verge Genomics Stock
Invest in or calculate the value of your shares in Verge Genomics or other pre-IPO companies through EquityZen's platform.
About Verge Genomics Stock
Founded
2015
Headquarters
San Francisco, CA, US
Notable Investor
WuXi AppTec
Total Funding
36.1M
Industries
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
Verge Genomics Press Mentions
Stay in the know about the latest news on Verge Genomics
Artificial Intelligence Discovers Molecules Market 2023 Growth Opportunities and Future Outlook | Top Companies ...
motionsonline • May, 4 2024
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
businesswire • May, 4 2024
Peninsula drug developer Verge Genomics strikes potential $122 million ALS drug deal with Ferrer - San Francisco ...
bizjournals • Apr, 6 2024
Ferrer signs $122M biobucks deal for ex-US license to Verge's phase 1 ALS therapy
fiercebiotech • Apr, 6 2024
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
globenewswire • Apr, 6 2024
Investors in Verge Genomics
Discover investors in Verge Genomics stock and explore their portfolio companies
Verge Genomics Management
Leadership team at Verge Genomics
Co-Founder & Chief Executive Officer
Alice Zhang
Chief Business Officer
Jane Rhodes
Join now and verify your accreditation status to gain access to:
- Verge Genomics current valuation
- Verge Genomics stock price
- Available deals in Verge Genomics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Verge Genomics stock?
Accredited investors can buy pre-IPO stock in companies like Verge Genomics through EquityZen funds. These investments are made available by existing Verge Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Verge Genomics stock?
Shareholders can sell their Verge Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
